🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 13 of 116

  1. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  2. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  3. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  4. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  5. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  6. LHRHa

    Janssen Cilag International NV

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial

  7. LI

    Teva Pharma GmbH

    Squamous Cell Carcinoma of the Oral Cavity

    phase 3 mab completed

    1 trial

  8. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  9. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  12. LORLATINIB

    Pfizer Australia Pty Ltd

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  13. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  14. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  15. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  16. Lapatinib

    Novartis Pharmaceuticals

    Neoplasms, Breast

    phase 3 small molecule terminated

    2 trials

  17. Lapatinib

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule completed

    1 trial

  18. Lenalidomide

    Celgene Europe Limited

    B-cell Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  19. Lenvatinib

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  20. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule terminated

    1 trial

  21. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 small molecule active

    1 trial

  22. Lerotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  23. Leuprorelin

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  24. Leuprorelin SR

    Takeda

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

  25. Levotiroxina Teva 25 microgrammi compresse

    Fondazione Telethon ETS

    Hodgkin and non Hodgkin lymphoma, Medulloblastoma

    phase 3 small molecule active

    1 trial

  26. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  27. Livmoniplimab, ATEZOLIZUMAB, TREMELIMUMAB, BEVACIZUMAB, Budigalimab, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  28. Locally sourced sterile 0.9% (w/v) sodium chloride, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  29. Locametz 25 micrograms kit for radiopharmaceutical preparation, ABIRATERONE , LEUPRORELIN , HISTRELIN , ENZALUTAMIDE , TRIPTORELIN , NILUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, GOSERELIN , DEGARELIX , BICALUTAMIDE , BUSERELIN , -, RELUGOLIX , APALUTAMIDE , DAROLUTAMIDE , FLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  30. Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  31. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  32. Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  33. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  34. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  35. Lynparza 100 mg film-coated tablets, ABIRATERONE , PREDNISOLONE , Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  36. Lynparza 100 mg film-coated tablets, Placebo - film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Breast Cancer

    phase 3 small molecule active

    1 trial

  37. Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB

    AstraZeneca AB

    Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  38. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  39. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    phase 3 small molecule active

    1 trial

  40. Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB

    Fondazione Telethon ETS

    Recurrent ovarian cancer

    phase 3 small molecule active

    1 trial

  41. MEDI4736

    AstraZeneca

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 mab completed

    1 trial

  42. MEDI4736

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  43. MEDI4736 (Durvalumab)

    AstraZeneca

    Non-Small-Cell Lung Carcinoma NSCLC

    phase 3 mab active

    1 trial

  44. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

  45. MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 small molecule active

    1 trial

  46. MEP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule terminated

    1 trial

  47. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  48. METHOTREXATE, DEXAMETHASONE, DEXAMETHASONE, CYTARABINE, CYTARABINE, DASATINIB, PREDNISOLONE, CYTARABINE, PONATINIB, CYTARABINE, METHOTREXATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISOLONE, IMATINIB MESILATE, METHOTREXATE, DEXAMETHASONE, Olverembatinib, DEXAMETHASONE, VINCRISTINE SULFATE, DEXAMETHASONE, DASATINIB, DEXAMETHASONE

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.